Evora Biosciences develops EVO-003, a patent-protected peptide targeting TLR4 to provide a selective anti-inflammatory effect for patients suffering from Acute Respiratory Distress Syndrome (ARDS). With no current treatment options available, EVO-003 demonstrates strong preclinical efficacy in reducing lung inflammation and improving recovery outcomes.
Funding
$600K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Acute Respiratory Distress Syndrome (ARDS) is a severe inflammatory lung condition with high mortality rates and no approved treatments. In ARDS, the patient's immune system attacks the lungs, leading to breathing difficulties and often requiring mechanical ventilation. Current supportive care strategies are often insufficient, leaving a significant unmet medical need.
Solution
Evora Biosciences is developing EVO-003, a novel, patent-protected peptide designed to selectively modulate the TLR4 receptor and reduce lung inflammation in ARDS patients. EVO-003 exhibits strong anti-inflammatory potency and a favorable safety profile, making it a promising immunomodulatory drug candidate. Preclinical in vivo studies suggest that EVO-003 promotes positive recovery from ARDS symptoms. By targeting TLR4, a validated target for ARDS treatment, EVO-003 offers a potential first-in-class therapeutic approach to address this critical unmet need. The peptide is stable, non-toxic, and amenable to multiple formulation options.
Target Audience
The primary target audience includes patients suffering from Acute Respiratory Distress Syndrome (ARDS) and the healthcare providers who treat them, specifically those in intensive care units (ICUs).
Features
- Novel, patent-protected peptide with a selective anti-inflammatory effect
- Targets TLR4, a validated target for ARDS treatment
- Demonstrated strong anti-inflammatory potency in preclinical studies
- Exhibits a favorable safety profile
- Stable and non-toxic
- Amenable to multiple formulation options